JP2015110607A5 - - Google Patents

Download PDF

Info

Publication number
JP2015110607A5
JP2015110607A5 JP2015003265A JP2015003265A JP2015110607A5 JP 2015110607 A5 JP2015110607 A5 JP 2015110607A5 JP 2015003265 A JP2015003265 A JP 2015003265A JP 2015003265 A JP2015003265 A JP 2015003265A JP 2015110607 A5 JP2015110607 A5 JP 2015110607A5
Authority
JP
Japan
Prior art keywords
oxadiazol
fluorophenyl
benzoic acid
water
crystallizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015003265A
Other languages
English (en)
Japanese (ja)
Other versions
JP6407733B2 (ja
JP2015110607A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015110607A publication Critical patent/JP2015110607A/ja
Publication of JP2015110607A5 publication Critical patent/JP2015110607A5/ja
Application granted granted Critical
Publication of JP6407733B2 publication Critical patent/JP6407733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015003265A 2006-09-25 2015-01-09 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形 Active JP6407733B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84732606P 2006-09-25 2006-09-25
US60/847,326 2006-09-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009529270A Division JP5714228B2 (ja) 2006-09-25 2007-09-24 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017106030A Division JP6495375B2 (ja) 2006-09-25 2017-05-29 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形

Publications (3)

Publication Number Publication Date
JP2015110607A JP2015110607A (ja) 2015-06-18
JP2015110607A5 true JP2015110607A5 (https=) 2017-07-27
JP6407733B2 JP6407733B2 (ja) 2018-10-17

Family

ID=39123850

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2009529270A Active JP5714228B2 (ja) 2006-09-25 2007-09-24 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形
JP2015003265A Active JP6407733B2 (ja) 2006-09-25 2015-01-09 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形
JP2017106030A Active JP6495375B2 (ja) 2006-09-25 2017-05-29 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形
JP2019040137A Withdrawn JP2019104752A (ja) 2006-09-25 2019-03-06 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形
JP2021090763A Active JP7245868B2 (ja) 2006-09-25 2021-05-31 3-[5-(2-フルオロフェニル)-[1,2,4]オキサジアゾール-3-イル]-安息香酸の結晶形
JP2023038770A Pending JP2023078271A (ja) 2006-09-25 2023-03-13 3-[5-(2-フルオロフェニル)-[1,2,4]オキサジアゾール-3-イル]-安息香酸の結晶形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009529270A Active JP5714228B2 (ja) 2006-09-25 2007-09-24 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017106030A Active JP6495375B2 (ja) 2006-09-25 2017-05-29 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形
JP2019040137A Withdrawn JP2019104752A (ja) 2006-09-25 2019-03-06 3−[5−(2−フルオロフェニル)−[1,2,4]オキサジアゾール−3−イル]−安息香酸の結晶形
JP2021090763A Active JP7245868B2 (ja) 2006-09-25 2021-05-31 3-[5-(2-フルオロフェニル)-[1,2,4]オキサジアゾール-3-イル]-安息香酸の結晶形
JP2023038770A Pending JP2023078271A (ja) 2006-09-25 2023-03-13 3-[5-(2-フルオロフェニル)-[1,2,4]オキサジアゾール-3-イル]-安息香酸の結晶形

Country Status (29)

Country Link
US (10) US7863456B2 (https=)
EP (2) EP2076501B8 (https=)
JP (6) JP5714228B2 (https=)
KR (1) KR101430144B1 (https=)
CN (3) CN104341371A (https=)
AR (2) AR062963A1 (https=)
AU (1) AU2007300542B2 (https=)
BR (1) BRPI0717107A2 (https=)
CA (1) CA2663574C (https=)
CL (1) CL2007002743A1 (https=)
DK (1) DK2076501T3 (https=)
ES (2) ES2655338T3 (https=)
HK (1) HK1207070A1 (https=)
HU (1) HUE028503T2 (https=)
IL (1) IL197717A (https=)
LT (1) LTC2076501I2 (https=)
MX (2) MX2009003160A (https=)
MY (1) MY191209A (https=)
NO (1) NO341858B1 (https=)
NZ (1) NZ575795A (https=)
PE (3) PE20120768A1 (https=)
PL (2) PL2559689T3 (https=)
PT (1) PT2076501E (https=)
SG (2) SG10201609581TA (https=)
SI (1) SI2076501T1 (https=)
TW (2) TWI496775B (https=)
UA (1) UA99600C2 (https=)
WO (1) WO2008039431A2 (https=)
ZA (1) ZA200901949B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
PL2402002T3 (pl) * 2005-04-08 2018-11-30 Ptc Therapeutics, Inc. Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
EP2387995A1 (en) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
NZ575795A (en) * 2006-09-25 2012-03-30 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
MX2009003909A (es) 2006-10-12 2009-05-25 Ptc Therapeutics Inc Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
WO2014165673A1 (en) 2013-04-03 2014-10-09 Colorado Energy Research Technologies, LLC Methods and systems for generating aldehydes from organic seed oils
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
TWI695717B (zh) * 2014-03-06 2020-06-11 美商 Ptc 治療公司 1,2,4-二唑苯甲酸之鹽及醫藥組合物
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
NZ734650A (en) 2015-03-10 2023-07-28 Aurigene Oncology Ltd 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN108348527A (zh) 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
EP3512516A1 (en) * 2016-09-13 2019-07-24 Marco Cipolli Method of treatment of shwachman-diamond syndrome
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
IL273896B2 (en) 2017-10-11 2025-08-01 Aurigene Oncology Ltd Crystalline forms of 3-substituted 1,2,4-oxadiazole
AU2018360386B2 (en) 2017-11-03 2023-11-09 Aurigene Oncology Limited Dual inhibitors of TIM-3 and PD-1 pathways
CN111386128A (zh) 2017-11-06 2020-07-07 奥瑞基尼探索技术有限公司 用于免疫调节的联合疗法
EP4473971A3 (en) 2019-04-10 2025-02-19 PTC Therapeutics, Inc. Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
JP7339900B2 (ja) * 2020-02-26 2023-09-06 新 井上 視野異常診断方法、視野異常診断装置
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
WO2025110781A1 (ko) * 2023-11-24 2025-05-30 재단법인 아산사회복지재단 Ampd3를 포함하는 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 ampd3 저해제를 포함하는 신경섬유종증 예방 또는 치료용 약학 조성물
CN118178408A (zh) * 2024-03-22 2024-06-14 核工业总医院 Ptc124在制备治疗血小板无力症的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW264475B (https=) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
KR20040004705A (ko) 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
WO2004001010A2 (en) * 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US8374966B1 (en) * 2002-08-01 2013-02-12 Oracle International Corporation In memory streaming with disk backup and recovery of messages captured from a database redo stream
MXPA05001592A (es) 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP4101846B1 (en) * 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
EP1799659A1 (en) * 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
CA2588994A1 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
PL2402002T3 (pl) * 2005-04-08 2018-11-30 Ptc Therapeutics, Inc. Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
UA99265C2 (ru) 2006-09-08 2012-08-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)
NZ575795A (en) * 2006-09-25 2012-03-30 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
TWI695717B (zh) * 2014-03-06 2020-06-11 美商 Ptc 治療公司 1,2,4-二唑苯甲酸之鹽及醫藥組合物

Similar Documents

Publication Publication Date Title
JP2015110607A5 (https=)
JP2013049690A5 (https=)
HRP20241723T1 (hr) Kristalni toluen solvat od (s)-afoksolanera
JP2018538331A5 (https=)
JP2018520178A5 (https=)
US10364225B2 (en) Process for preparing boscalid
TWI756173B (zh) 製備啶醯菌胺之方法
CN120289331A (zh) 一种简易且能控制晶型的高纯甲脒氢碘酸盐的制备方法
TWI687413B (zh) 製備吡蟲啉(imidacloprid)多晶型的方法
CN103613552A (zh) 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
JP2017507994A5 (ja) チアクマイシンbの新たな溶媒和結晶
CN106432253B (zh) 一种维帕他韦新晶型及其制备方法
KR101589910B1 (ko) 결정형 α 탈티레린의 제조방법 및 결정형의 변환방법
WO2010108417A1 (zh) 阿昔洛韦2/3水合物的制备方法
TWI914060B (zh) 異噁唑啉脲嘧啶類化合物的結晶方法及其應用
Czapla et al. Structural phase transition and ferroelasticity in (H2NNH3) 3CdBr5 crystal
US20100274007A1 (en) Process for preparing polymorphic forms of (s)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
CN105801558A (zh) 一种四氯虫酰胺晶体及其制备方法
WO2021134921A1 (zh) 一种啶嘧磺隆晶型及其制备方法
CN106220639A (zh) 一种维帕他韦中间体新晶型
WO2021134943A1 (zh) 一种啶嘧磺隆晶型及其制备方法
KR101010062B1 (ko) 증발 결정화를 이용한 결정상 리세드로네이트 모노소듐모노하이드레이트의 제조방법
WO2016034602A1 (en) Solid forms of (2s,4r)-4-[4-(1-methyl-1h-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide
CN104788475B (zh) 一种金属‑有机框架DMMgF单晶材料及其制备方法
CN104788476A (zh) 一种金属-有机框架DMCaF单晶材料及其制备方法